» Articles » PMID: 2653696

Pharmacokinetic Disposition of Quinolones in Human Body Fluids and Tissues

Overview
Specialty Pharmacology
Date 1989 Jan 1
PMID 2653696
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

The unique pharmacokinetic properties as well as the body fluid and tissue penetration of quinolones are discussed. Quinolones are well absorbed from the gastrointestinal tract and are eliminated with considerable differences in their terminal half-lives. The major elimination pathways of quinolones are renal excretion and hepatic metabolism. Renally, these drugs undergo the potential excretion mechanisms (glomerular filtration, tubular secretion, reabsorption). In the liver, they are metabolised primarily by oxidation as well as by conjugative pathways. However, the metabolic pattern and extent of metabolism differ significantly between individual agents. Alterations in the pharmacokinetic disposition of these agents in liver and renal failure as well as in elderly patients are observed as predicted from their excretion pattern. In addition, quinolones can interact with a number of other compounds at hepatic (e.g. with xanthine derivatives), renal (with probenecid) and gastrointestinal (with antacids) sites. The volume of distribution of quinolones is considerably higher than body volume, which suggests intracellular penetration. Studies on tissue penetration show that concentrations exceeding plasma levels are obtained in most tissues. The highest tissue/plasma concentration ratios are achieved in lung and kidney, whereas concentrations in fat are considerably lower than in plasma. Body fluid penetration is introduced as a new approach to evaluate distribution kinetics of quinolones. With the exception of those in nasal secretions and ejaculate, body fluid levels of these drugs rarely reach plasma levels. The body fluid penetration model allows for differentiation among individual agents. There is no apparent relationship between differences in body fluid penetration of quinolones and differences in volume of distribution. For the clinical use of these drugs it is important that the concentrations achieved in body fluids and tissues are sufficient to kill most pathogens. A discussion on the relationship between plasma and tissue levels and the MICs of quinolones is, however, beyond the scope of this article.

Citing Articles

Comparable Bioavailability and Disposition of Pefloxacin in Patients with Cystic Fibrosis and Healthy Volunteers Assessed via Population Pharmacokinetics.

Bulitta J, Jiao Y, Landersdorfer C, Sutaria D, Tao X, Shin E Pharmaceutics. 2019; 11(7).

PMID: 31295857 PMC: 6681055. DOI: 10.3390/pharmaceutics11070323.


Intestinal ciprofloxacin efflux: the role of breast cancer resistance protein (ABCG2).

Haslam I, Wright J, OReilly D, Sherlock D, Coleman T, Simmons N Drug Metab Dispos. 2011; 39(12):2321-8.

PMID: 21930826 PMC: 3226371. DOI: 10.1124/dmd.111.038323.


Survey: calculation of the characteristics of oral diffusion-controlled release dosage forms related to the drug.

Rosca I, Vergnaud J Eur J Drug Metab Pharmacokinet. 2011; 35(1-2):29-39.

PMID: 21495264 DOI: 10.1007/s13318-010-0005-x.


Ciprofloxacin bioavailability is enhanced by oral co-administration with phenazopyridine: a pharmacokinetic study in a Mexican population.

Marcelin-Jimenez G, Angeles A, Martinez-Rossier L, Fernandez S A Clin Drug Investig. 2006; 26(6):323-8.

PMID: 17163266 DOI: 10.2165/00044011-200626060-00003.


Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats.

Yamaguchi H, Yano I, Saito H, Inui K Pharm Res. 2004; 21(2):330-8.

PMID: 15032316 DOI: 10.1023/b:pham.0000016247.44589.f1.


References
1.
Wise R . The clinical relevance of protein binding and tissue concentrations in antimicrobial therapy. Clin Pharmacokinet. 1986; 11(6):470-82. DOI: 10.2165/00003088-198611060-00004. View

2.
Fong I, Vandenbroucke A, Simbul M . Penetration of enoxacin into bronchial secretions. Antimicrob Agents Chemother. 1987; 31(5):748-51. PMC: 174826. DOI: 10.1128/AAC.31.5.748. View

3.
Bergeron M, Thabet M, Roy R, Lessard C, Foucault P . Norfloxacin penetration into human renal and prostatic tissues. Antimicrob Agents Chemother. 1985; 28(2):349-50. PMC: 180245. DOI: 10.1128/AAC.28.2.349. View

4.
Klinge E, Mannisto P, Mantyla R, Mattila J, Hanninen U . Single- and multiple-dose pharmacokinetics of pipemidic acid in normal human volunteers. Antimicrob Agents Chemother. 1984; 26(1):69-73. PMC: 179919. DOI: 10.1128/AAC.26.1.69. View

5.
Wise R, Lister D, McNulty C, Griggs D, Andrews J . The comparative pharmacokinetics of five quinolones. J Antimicrob Chemother. 1986; 18 Suppl D:71-81. DOI: 10.1093/jac/18.supplement_d.71. View